Centessa IPO Presentation Deck

Z Factor Developing Phase 1 and preclinical stage folding correctors for Z-variant of alpha-1-antitrypsin (A1AT), to treat both liver and lung disease manifestations of A1AT deficiency Mission Develop a potent and specific catalytic folding corrector of Z-A1AT to increase serum levels and reduce liver burden to treat liver and lung disease manifestations of A1AT deficiency De-risking data ZF874 increased levels of active Z-A1AT in the blood and improved markers of liver pathology in Piz mice Seven cohorts of healthy volunteers successfully dosed up to 50mg/kg of ZF874 with excellent oral bioavailability and all doses well tolerated except for transient apparent Cmax effect at 50mg/kg in fasted state ZFactor Market opportunity Estimated prevalence of 200,000 Pizz individuals worldwide PiMZ prevalence of 42.4 million individuals and observed in large subset of COPD and NASH populations CENTESSA 22

View entire presentation